{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.694","upperLimit":"2.760","value":"2.727"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"description":"TTR by IRF per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was the time from date of first study drug administration to date of first documented objective response (CR or PR) by IRF following the completion of study treatment for responders. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received brentuximab vedotin 1.8 mg/kg, IV infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\\^2 and doxorubicin 50 mg/m\\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until PD, unacceptable toxicity, whichever occurred first.","id":"OG000","title":"Brentuximab Vedotin + CHP"}],"paramType":"MEDIAN","populationDescription":"The FAS consisted of all enrolled participants. Here, \"overall number of participants analyzed\" signifies the number of participants with data available for analysis of this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 7 months","title":"Time to Response (TTR) by IRF Per 2014 Lugano Classification","type":"SECONDARY","unitOfMeasure":"months"}